Ovarian Cancer Biomarkers: Moving Forward in Early Detection

Adv Exp Med Biol. 2020;1219:355-363. doi: 10.1007/978-3-030-34025-4_18.

Abstract

Ovarian cancer is a silent cancer which rate survival mainly relays in early stage detection. The discovery of reliable ovarian cancer biomarkers plays a crucial role in the disease management and strongly impact in patient's prognosis and survival. Although having many limitations CA125 is a classical ovarian cancer biomarker, but current research using proteomic or metabolomic methodologies struggles to find alternative biomarkers, using non-invasive our relatively non-invasive sources such as urine, serum, plasma, tissue, ascites or exosomes. Metabolism and metabolites are key players in cancer biology and its importance in biomarkers discovery cannot be neglected. In this chapter we overview the state of art and the challenges facing the use and discovery of biomarkers and focus on ovarian cancer early detection.

Keywords: Cancer biomarkers; Early detection; Metabolomics; Ovarian cancer; Proteomics; Urine biomarkers.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / metabolism
  • CA-125 Antigen / analysis
  • CA-125 Antigen / metabolism
  • Early Detection of Cancer*
  • Female
  • Humans
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / metabolism*
  • Proteomics

Substances

  • Biomarkers, Tumor
  • CA-125 Antigen